FDA Grants Fast Track and Orphan Drug Designations to NBM-BMX for Metastatic Uveal Melanoma
核心洞察
The FDA has granted both Fast Track and Orphan Drug Designation to NBM-BMX, a selective HDAC8 (搜索) inhibitor developed by NovelWise Pharmaceutical Corporation for treating metastatic uveal melanoma (搜索).
NBM-BMX targets BAP1 (搜索)-associated epigenetic dysregulation in uveal melanoma (搜索) and has demonstrated safety in prior phase 1 studies with advanced solid tumors (搜索).
The Orphan Drug Designation provides seven years of market exclusivity, waiver of FDA filing fees, and 25% federal tax credit on clinical trial expenses.
The FDA has granted both Fast Track designation and Orphan Drug Designation (ODD) to NBM-BMX, a selective HDAC8 (搜索) inhibitor developed by NovelWise Pharmaceutical Corporation for the treatment of metastatic uveal melanoma (搜索). These regulatory milestones represent significant progress for addressing an aggressive rare cancer with limited treatment options.
Targeting BAP1-Associated Epigenetic Dysregulation
NBM-BMX is designed to moderate epigenetic mechanisms in solid tumors, specifically targeting BAP1 (搜索)-associated epigenetic dysregulation that plays an important role in uveal melanoma (搜索) tumor progression. The agent functions as a next-generation HDAC8 (搜索)-selective inhibitor designed to modulate tumor DNA repair and survival pathways.
The FDA's decision to grant Fast Track status was supported by preclinical findings in uveal melanoma (搜索) models and safety data from prior phase 1 clinical studies. According to NovelWise, "This designation will facilitate more efficient regulatory interactions and clinical planning, helping shorten the time needed to bring new treatment options to patients in need."
Clinical Development Program
The phase 1/2 NBM-BMX-UM trial (NCT07136181) will evaluate the safety, efficacy, and pharmacokinetics of NBM-BMX in patients with metastatic uveal melanoma (搜索). The study will enroll patients with histologically or cytologically confirmed metastatic uveal melanoma who are at least 18 years of age, have an ECOG performance status no higher than 2, and measurable disease by RECIST 1.1 criteria.
NBM-BMX will be examined at four dose levels: 200 mg daily or 100 mg twice daily (dose level 1), 400 mg daily or 200 mg twice daily (dose level 2), 600 mg daily or 300 mg twice daily (dose level 3), and 800 mg daily or 400 mg twice daily (dose level 4). A total daily dose of 600 mg dry powder formulation has been deemed well tolerated in patients with advanced solid tumors (搜索), with three patients completing treatment without experiencing dose-limiting toxicities.
The primary outcome measures for the phase 1b portion include evaluating incidence of dose-limiting toxicities and determining the maximum tolerated dose. For the phase 2 portion, primary outcome measures include objective response rate, 3-month progression-free survival rate, and overall survival.
Regulatory Benefits and Market Impact
The Orphan Drug Designation provides substantial regulatory and commercial advantages, including seven years of U.S. market exclusivity upon approval, waiver of FDA PDUFA filing fee (approximately $4.4 million in 2025), and 25% federal tax credit on U.S. clinical trial expenses. The designation also enables enhanced FDA regulatory guidance, more frequent scientific interactions, and eligibility for Accelerated Approval and Rolling Review.
John Soong, MD, Chief Executive Officer of NovelWise, commented: "Receiving both Fast Track Designation and now Orphan Drug Designation underscores NBM-BMX's promise in addressing a high unmet medical need for patients with uveal melanoma (搜索). These regulatory milestones will accelerate the development pathway for NBM-BMX and support our mission of delivering innovative therapy options to patients suffering from rare and aggressive cancers."
Broader Clinical Investigation
NBM-BMX has been evaluated in multiple completed phase 1 studies. A prior open-label, phase 1, dose-escalation study (NCT03726294) examined the safety, tolerability, pharmacokinetics and efficacy in patients with advanced solid tumors (搜索). Another completed study (NCT03808870) evaluated the agent specifically in Asian patients with advanced solid tumors.
Currently, NBM-BMX is under evaluation in an open-label, multicenter, 2-arm, phase 1b/2 trial (NCT06012695) as monotherapy in patients with advanced solid tumors (搜索) or in combination with standard-of-care treatment in those with newly diagnosed glioblastoma (搜索). NovelWise noted that "insights from that program are expected to further optimize the development strategy for metastatic uveal melanoma (搜索)."
Market Opportunity
According to Smart Insights Market Research, the global uveal melanoma (搜索) treatment market was valued at $650 million in 2022 and is projected to reach $1.25 billion by 2030, representing a compound annual growth rate of 8.5%. NovelWise is conducting its clinical program in collaboration with ten leading cancer centers across the United States, with three sites having completed Site Initiation Visits and the study progressing toward expanded activation and enrollment.